Stock Traders Buy High Volume of Call Options on Alumis (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) saw some unusual options trading activity on Monday. Stock investors bought 5,003 call options on the stock. This is an increase of approximately 147% compared to the typical volume of 2,026 call options.

Analyst Ratings Changes

A number of brokerages have commented on ALMS. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Alumis in a research report on Wednesday, March 26th. Oppenheimer assumed coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Down 6.0 %

ALMS opened at $4.70 on Tuesday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The business’s 50 day moving average is $5.55 and its two-hundred day moving average is $7.81.

Insider Buying and Selling at Alumis

In other news, Director Alan Colowick bought 16,104 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were purchased at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the purchase, the director now owns 16,104 shares of the company’s stock, valued at approximately $112,244.88. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martin Babler bought 15,650 shares of Alumis stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the acquisition, the chief executive officer now owns 106,454 shares of the company’s stock, valued at $685,563.76. This represents a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Trading of Alumis

Several institutional investors and hedge funds have recently bought and sold shares of ALMS. Wells Fargo & Company MN increased its stake in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alumis in the 4th quarter valued at approximately $79,000. Rhumbline Advisers increased its holdings in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Marshall Wace LLP purchased a new stake in shares of Alumis during the fourth quarter worth approximately $108,000. Finally, XTX Topco Ltd acquired a new stake in shares of Alumis during the fourth quarter worth $129,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.